- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Shortened Shelf Life Prompts Recall of Nasal H1N1 Vaccine
MedImmune is recalling 13 lots of monovalent 2009 H1N1 influenza nasal spray vaccine whose potency has decreased or is expected to decrease shortly.
MedImmune is recalling 13 lots of monovalent 2009 H1N1 influenza nasal spray vaccine whose potency has decreased or is expected to decrease shortly. The slight reduction in potency should not affect the ability of the vaccine to stimulate a protective response. Thus, there is no need to re-administer a dose to patients who received vaccine from the affected lots.
About 4.7 million doses were in these lots. Most of the doses were shipped to vaccine providers in October and early November, during a time when the vaccine potency was still at or above the recommended level.
The manufacturer will notify providers who received doses from any of the affected lots so that they can return any unused vaccine.
The affected lot numbers are:
500754P
500751P
500756P
500757P
500758P
500759P
500760P
500761P
500762P
500763P
500764P
500765P
500776P
